NASDAQ:EXEL

Exelixis News Headlines

$23.22
-0.75 (-3.13 %)
(As of 05/6/2021 12:00 AM ET)
Add
Compare
Today's Range
$22.78
▼
$23.84
50-Day Range
$21.87
▼
$24.86
52-Week Range
$18.18
▼
$27.80
Volume1.90 million shs
Average Volume2.03 million shs
Market Capitalization$7.27 billion
P/E Ratio48.38
Dividend YieldN/A
Beta1.21

Headlines

Exelixis (NASDAQ EXEL) News Headlines Today

SourceHeadline
Exelixis (NASDAQ:EXEL) PT Lowered to $26.00Exelixis (NASDAQ:EXEL) PT Lowered to $26.00
marketbeat.com - April 26 at 9:07 AM
Should Value Investors Buy ABM Industries (ABM) Stock? - NasdaqShould Value Investors Buy ABM Industries (ABM) Stock? - Nasdaq
nasdaq.com - May 7 at 3:23 AM
Exelixis (EXEL) Reports Break-Even Earnings for Q1 - Yahoo FinanceExelixis (EXEL) Reports Break-Even Earnings for Q1 - Yahoo Finance
finance.yahoo.com - May 6 at 10:22 PM
Exelixis (EXEL) Reports Break-Even Earnings for Q1Exelixis (EXEL) Reports Break-Even Earnings for Q1
finance.yahoo.com - May 6 at 10:22 PM
Exelixis (NASDAQ:EXEL) Issues FY 2021 Earnings GuidanceExelixis (NASDAQ:EXEL) Issues FY 2021 Earnings Guidance
americanbankingnews.com - May 6 at 10:20 PM
Exelixis Announces First Quarter 2021 Financial Results and Provides Corporate Update - Yahoo FinanceExelixis Announces First Quarter 2021 Financial Results and Provides Corporate Update - Yahoo Finance
finance.yahoo.com - May 6 at 5:22 PM
Exelixis Announces First Quarter 2021 Financial Results and Provides Corporate UpdateExelixis Announces First Quarter 2021 Financial Results and Provides Corporate Update
finance.yahoo.com - May 6 at 5:22 PM
Exelixis (EXEL) Announces Acquisition of GamaMabs Pharmas First-in-Class Humanized Antibody Program Against a Novel Oncology Target - StreetInsider.comExelixis (EXEL) Announces Acquisition of GamaMabs Pharma's First-in-Class Humanized Antibody Program Against a Novel Oncology Target - StreetInsider.com
streetinsider.com - May 5 at 11:17 AM
Heres what to expect from Exelixiss earningsHere's what to expect from Exelixis's earnings
markets.businessinsider.com - May 4 at 7:22 PM
Exelixis Expands its Biotherapeutics Portfolio with Acquisition of GamaMabs Pharma’s First-in-Class Humanized Antibody Program Against a Novel Oncology TargetExelixis Expands its Biotherapeutics Portfolio with Acquisition of GamaMabs Pharma’s First-in-Class Humanized Antibody Program Against a Novel Oncology Target
finance.yahoo.com - May 4 at 9:21 AM
Exelixis, Inc. (NASDAQ:EXEL) EVP Patrick J. Haley Sells 7,665 SharesExelixis, Inc. (NASDAQ:EXEL) EVP Patrick J. Haley Sells 7,665 Shares
americanbankingnews.com - April 28 at 10:46 PM
Exelixis, Inc. (NASDAQ:EXEL) CMO Sells $1,250,000.00 in StockExelixis, Inc. (NASDAQ:EXEL) CMO Sells $1,250,000.00 in Stock
americanbankingnews.com - April 28 at 10:46 PM
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in May - Yahoo FinanceExelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in May - Yahoo Finance
finance.yahoo.com - April 28 at 8:14 AM
Is EXEL Stock A Buy or Sell? - Yahoo FinanceIs EXEL Stock A Buy or Sell? - Yahoo Finance
finance.yahoo.com - April 26 at 1:27 PM
Is EXEL Stock A Buy or Sell?Is EXEL Stock A Buy or Sell?
finance.yahoo.com - April 26 at 1:27 PM
Exelixis (NASDAQ:EXEL) Price Target Lowered to $26.00 at Morgan StanleyExelixis (NASDAQ:EXEL) Price Target Lowered to $26.00 at Morgan Stanley
americanbankingnews.com - April 26 at 10:28 AM
3 Top Biotech Picks to Buy and Hold for the Next 10 Years - Motley Fool3 Top Biotech Picks to Buy and Hold for the Next 10 Years - Motley Fool
fool.com - April 25 at 9:37 AM
Exelixis, Inc.s (NASDAQ:EXEL) Stock Is Going Strong: Have Financials A Role To Play? - Yahoo FinanceExelixis, Inc.'s (NASDAQ:EXEL) Stock Is Going Strong: Have Financials A Role To Play? - Yahoo Finance
finance.yahoo.com - April 24 at 1:26 PM
Exelixis, Inc.s (NASDAQ:EXEL) Stock Is Going Strong: Have Financials A Role To Play?Exelixis, Inc.'s (NASDAQ:EXEL) Stock Is Going Strong: Have Financials A Role To Play?
finance.yahoo.com - April 24 at 1:26 PM
Exelixis to Release First Quarter 2021 Financial Results on Thursday, May 6, 2021 - Business WireExelixis to Release First Quarter 2021 Financial Results on Thursday, May 6, 2021 - Business Wire
businesswire.com - April 22 at 11:52 PM
Exelixis to Release First Quarter 2021 Financial Results on Thursday, May 6, 2021Exelixis to Release First Quarter 2021 Financial Results on Thursday, May 6, 2021
finance.yahoo.com - April 22 at 6:51 PM
Morgan Stanley Lowers Exelixis (NASDAQ:EXEL) Price Target to $26.00Morgan Stanley Lowers Exelixis (NASDAQ:EXEL) Price Target to $26.00
americanbankingnews.com - April 19 at 11:32 AM
If You Had Bought Exelixis (NASDAQ:EXEL) Shares Five Years Ago Youd Have Earned 430% Returns - NasdaqIf You Had Bought Exelixis (NASDAQ:EXEL) Shares Five Years Ago You'd Have Earned 430% Returns - Nasdaq
nasdaq.com - April 16 at 9:20 AM
Bristol Myers (BMY) Opdivo Combo Gets EU Nod for First-Line RCC - NasdaqBristol Myers' (BMY) Opdivo Combo Gets EU Nod for First-Line RCC - Nasdaq
nasdaq.com - April 15 at 1:31 PM
Form DEF 14A EXELIXIS, INC. For: May 26 - StreetInsider.comForm DEF 14A EXELIXIS, INC. For: May 26 - StreetInsider.com
streetinsider.com - April 15 at 1:31 PM
3 Growth Stocks Thatll Make You Richer in Q2 (and Beyond) - Nasdaq3 Growth Stocks That'll Make You Richer in Q2 (and Beyond) - Nasdaq
nasdaq.com - April 8 at 1:21 PM
3 Growth Stocks Thatll Make You Richer in Q2 (and Beyond)3 Growth Stocks That'll Make You Richer in Q2 (and Beyond)
finance.yahoo.com - April 8 at 8:20 AM
Exelixis (EXEL) Announces US FDA Accepts IND Application for XB002 in Patients with Advanced Solid Tumors - StreetInsider.comExelixis (EXEL) Announces US FDA Accepts IND Application for XB002 in Patients with Advanced Solid Tumors - StreetInsider.com
streetinsider.com - April 7 at 9:14 AM
FDA accepts Exelixis XB002 application in advanced solid tumors - Seeking AlphaFDA accepts Exelixis' XB002 application in advanced solid tumors - Seeking Alpha
seekingalpha.com - April 6 at 11:36 PM
Exelixis Announces U.S. FDA Accepts Investigational New Drug Application for XB002 in Patients with Advanced Solid Tumors - Business WireExelixis Announces U.S. FDA Accepts Investigational New Drug Application for XB002 in Patients with Advanced Solid Tumors - Business Wire
businesswire.com - April 6 at 11:36 PM
Exelixis (EXEL) IND for Oncology Candidate Accepted by FDA - Yahoo FinanceExelixis' (EXEL) IND for Oncology Candidate Accepted by FDA - Yahoo Finance
finance.yahoo.com - April 6 at 1:35 PM
Exelixis (EXEL) IND for Oncology Candidate Accepted by FDAExelixis' (EXEL) IND for Oncology Candidate Accepted by FDA
finance.yahoo.com - April 6 at 1:35 PM
Exelixis Announces U.S. FDA Accepts Investigational New Drug Application for XB002 in Patients with Advanced Solid TumorsExelixis Announces U.S. FDA Accepts Investigational New Drug Application for XB002 in Patients with Advanced Solid Tumors
finance.yahoo.com - April 5 at 12:50 PM
Royalty Pharma Buys Royalty Interest In Cabozantinib Products From GSK - Yahoo FinanceRoyalty Pharma Buys Royalty Interest In Cabozantinib Products From GSK - Yahoo Finance
finance.yahoo.com - April 1 at 11:48 PM
Exelixis (EXEL) Partner Gets EC Nod for Cabometyx + Opdivo - Yahoo FinanceExelixis (EXEL) Partner Gets EC Nod for Cabometyx + Opdivo - Yahoo Finance
finance.yahoo.com - April 1 at 6:48 PM
Exelixis (EXEL) Partner Gets EC Nod for Cabometyx + OpdivoExelixis (EXEL) Partner Gets EC Nod for Cabometyx + Opdivo
finance.yahoo.com - April 1 at 1:40 PM
Royalty Pharma (RPRX) Acquires Royalty Interest in Cabozantinib From GSK (GSK) - StreetInsider.comRoyalty Pharma (RPRX) Acquires Royalty Interest in Cabozantinib From GSK (GSK) - StreetInsider.com
streetinsider.com - April 1 at 8:39 AM
Royalty Pharma Acquires Royalty Interest in Cabozantinib From GSK - StreetInsider.comRoyalty Pharma Acquires Royalty Interest in Cabozantinib From GSK - StreetInsider.com
streetinsider.com - April 1 at 8:39 AM
Exelixis Announces Enrollment Completion in Phase 3 COSMIC-313 Pivotal Trial of Cabozantinib in Combination with Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell Carcinoma - Yahoo FinanceExelixis Announces Enrollment Completion in Phase 3 COSMIC-313 Pivotal Trial of Cabozantinib in Combination with Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell Carcinoma - Yahoo Finance
finance.yahoo.com - March 31 at 8:11 PM
Exelixis’ partner Ipsen win EU approval for Cabometyx combo in kidney cancer - Seeking AlphaExelixis’ partner Ipsen win EU approval for Cabometyx combo in kidney cancer - Seeking Alpha
seekingalpha.com - March 31 at 8:11 PM
Exelixis Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma - Business WireExelixis' Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma - Business Wire
businesswire.com - March 31 at 5:01 AM
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as First-Line Treatment for Patients with Advanced Renal Cell CarcinomaExelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
finance.yahoo.com - March 31 at 5:01 AM
Exelixis: A Look At Its Potential - Seeking AlphaExelixis: A Look At Its Potential - Seeking Alpha
seekingalpha.com - March 30 at 7:01 PM
Exelixis Announces Enrollment Completion in Phase 3 COSMIC-313 Pivotal Trial of Cabozantinib in Combination with Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell CarcinomaExelixis Announces Enrollment Completion in Phase 3 COSMIC-313 Pivotal Trial of Cabozantinib in Combination with Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell Carcinoma
finance.yahoo.com - March 30 at 9:00 AM
Exelixis Stock Is Believed To Be Fairly Valued - Yahoo FinanceExelixis Stock Is Believed To Be Fairly Valued - Yahoo Finance
finance.yahoo.com - March 29 at 12:58 PM
3 Exciting Biotech Stocks to Buy Right Now - Nasdaq3 Exciting Biotech Stocks to Buy Right Now - Nasdaq
nasdaq.com - March 27 at 8:42 AM
3 Exciting Biotech Stocks to Buy Right Now3 Exciting Biotech Stocks to Buy Right Now
finance.yahoo.com - March 27 at 8:42 AM
June 18th Options Now Available For Exelixis (EXEL) - NasdaqJune 18th Options Now Available For Exelixis (EXEL) - Nasdaq
nasdaq.com - March 26 at 3:00 PM
Exelixis Stock Appears To Be Modestly Undervalued - Yahoo FinanceExelixis Stock Appears To Be Modestly Undervalued - Yahoo Finance
finance.yahoo.com - March 25 at 12:34 AM
First Week of November 19th Options Trading For Exelixis (EXEL) - NasdaqFirst Week of November 19th Options Trading For Exelixis (EXEL) - Nasdaq
nasdaq.com - March 19 at 5:21 PM
Exelixis Partners With Merck KGaA And Pfizer For STELLAR-001 Clinical Trial - Yahoo FinanceExelixis Partners With Merck KGaA And Pfizer For STELLAR-001 Clinical Trial - Yahoo Finance
finance.yahoo.com - March 19 at 5:21 PM
This page was last updated on 5/7/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.